Vantage logo

Full steam ahead at F2G

The UK developer has the launch of what could be the first in a new class of antifungals in its sights.

Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Vantage logo

T3D puts a bet on Alzheibetes

An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.